AmideBio is a preclinical stage biotech company pursuing a series of therapeutic targets and diagnostic in the diabetes space. The companies lead program is focused on novel forms of glucose responsive insulins (GRIs) that will eliminate the need for both basal and prandial insulins through a single weekly dose. This program leverages the company’s novel insights, computational design capabilities and strong IP position in rapid manufacturing of ultrapure biologics. Importantly, these novel GRIs do not require complex chemical modifications and respond in real-time to blood glucose levels which is expected to dramatically improve glycemic control and virtually eliminate hypoglycemic events. While AmideBio is single minded in our pursuit to bring a novel GRI to the clinic, we will maintain support for a number of our legacy programs through appropriate partnerships. These programs include single chain insulin (SCI) analogs that are resistant to thermal and chemical degradation at elevated temperature, solution stable glucagon analogues suitable for use in pumps for an artificial pancreas or the treatment of rare diseases such as congenital hyperinsulinism, and early diagnostics for T1D. The company will continue using our proprietary BioPure™ platform technology to deliver difficult-to-manufacture peptides for the research community.